Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment

Gilead Sciences announced Monday pricing for its coronavirus treatment remdesivir, saying it will cost $3,120 for a typical U.S. patient with commercial insurance. Gilead CEO Daniel O'Day joins "Squawk Box" to discuss the price tag as well as ensuring patients have access to the drug and concerns surrounding the supply chain.